Riskpilot← Back to searchSign inGet full accessRidahpharma AB
ABActiveOrg 5568196553Carl-Gustaf Lindstedts Gata 8Wholesale of perfume and cosmetics · NACE 4645Est. 20100 employees
Revenue 2025
SEK -1
-100% vs 2024
EBITDA margin
31168000.0%
+2% vs 2024
Equity ratio
98.6%
Financial strength
Net profit 2025
SEK -212K
-21% vs 2024
| Revenue | SEK -1 | -100% |
| EBITDA | SEK -312K | +2% |
| Net profit | SEK -212K | -21% |
| Total assets | SEK 1,5M | -12% |
| Equity | SEK 1,5M | -12% |
| Employees | 0 | — |
Legal name
Ridahpharma AB
Org number
5568196553
Legal form
Aktiebolag
NACE code
4645 · Wholesale of perfume and cosmetics
Founded
22 september 2010
Share capital
SEK 100 000
Employees
0
VAT registered
Yes
Audit selected
No
Last report
2025-12-31
Financial year
January – December
Signatory rights
Firman tecknas av styrelsen Firman tecknas var för sig av ledamöterna
Company purpose
Bolaget ska bedriva handel med, distribution och försäljning av sjukvårds- och läkemedelsprodukter för hälso-, sjuk- och friskvård samt apotek inom Sverige och övriga Europa. Därtill ska bolaget utöva konsultverksamhet inom läkemedelsbranschen. Bolaget ska även äga och förvalta värdepapper samt förvalta fast egendom, samt bedriva därmed förenlig verksamhet. Företaget ska bedriva konsultverksamhet inom tandvård och hälsoekonomi.
Address
Carl-Gustaf Lindstedts Gata 8
Email
adam.ridahsson@ridahpharma.com
Risika for professionals
Risika provides regulated workflow tools for finance, procurement and compliance teams that need monitoring, alerts and an API.
| Item | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | — | — | 0 | 0 | 1 004 | 2 259 | 0 | 0 | 49 | 40 | −0 |
| Staff expenses | — | — | — | — | — | — | — | — | −0 | −133 | −0 |
| EBITDA | −365 | −126 | −47 | −263 | −80 | −702 | −405 | −374 | −247 | −317 | −312 |
| Depreciation & amort. | −0 | −0 | −0 | −6 | −22 | −22 | −0 | −0 | — | — | — |
| EBIT | −365 | −126 | −47 | −269 | −102 | −724 | −405 | −374 | −247 | −317 | −312 |
| Net financials | 302 | −2 150 | −3 900 | — | — | 441 | 38 | 2 092 | 1 | 141 | 99 |
| Profit before tax | −62 | −2 276 | −3 947 | −269 | 498 | 802 | −367 | 1 718 | −245 | −175 | −212 |
| Tax | −0 | −0 | −0 | −0 | −0 | −0 | −0 | −0 | — | — | — |
| Net profit | −62 | −2 276 | −3 947 | −269 | 498 | 802 | −367 | 1 718 | −245 | −175 | −212 |
| Item | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Total assets | 8 356 | 5 683 | 2 016 | 1 644 | 2 180 | 2 913 | 2 478 | 2 177 | 1 931 | 1 760 | 1 544 |
| Equity | 7 840 | 5 564 | 1 617 | 1 348 | 1 846 | 2 804 | 2 437 | 2 155 | 1 910 | 1 735 | 1 522 |
| Long-term debt | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | — | — | — |
| Short-term debt | 516 | 119 | 399 | 296 | 334 | 108 | 41 | 21 | 21 | 25 | 21 |
| Total debt | 516 | 119 | 399 | 296 | 334 | 108 | 41 | 21 | 21 | 25 | 21 |
EBITDA margin
-31168000.0%
This company
15.8%
Market median
-197265923% vs market
20152025
Equity ratio
98.6%
This company
38.2%
Market median
+158% vs market
20152025
Return on equity
-14.0%
This company
18.4%
Market median
-176% vs market
20152025
Net profit margin
-21241400.0%
This company
8.1%
Market median
-262239606% vs market
20152025
Asset turnover
-0.00×
This company
1.12×
Market median
-100% vs market
20152025
Debt / equity
0.01×
This company
0.62×
Market median
+98% vs market
20152025
- Annual report 2025Filed via Bolagsverket / SCB · Period 2025-01-01 – 2025-12-31
- Annual report 2024Filed via Bolagsverket / SCB · Period 2024-01-01 – 2024-12-31
- Annual report 2023Filed via Bolagsverket / SCB · Period 2023-01-01 – 2023-12-31
- Annual report 2022Filed via Bolagsverket / SCB · Period 2022-01-01 – 2022-12-31
- Annual report 2021Filed via Bolagsverket / SCB · Period 2021-01-01 – 2021-12-31
- Annual report 2020Filed via Bolagsverket / SCB · Period 2020-01-01 – 2020-12-31
- Annual report 2019Filed via Bolagsverket / SCB · Period 2019-01-01 – 2019-12-31
- Annual report 2018Filed via Bolagsverket / SCB · Period 2018-01-01 – 2018-12-31
- Annual report 2017Filed via Bolagsverket / SCB · Period 2017-01-01 – 2017-12-31
- Annual report 2016Filed via Bolagsverket / SCB · Period 2016-01-01 – 2016-12-31
- Annual report 2015Filed via Bolagsverket / SCB · Period 2015-01-01 – 2015-12-31
| Name | Role | Member since | Age | Other directorships |
|---|---|---|---|---|
AM Chief Executive Officer | Chief Executive Officer | 2023 | — | — |
LM Chief Auditor | Chief Auditor | 2021 | — | — |
GI | Audit | 2022 | — | — |
| Name | Role | Member since | Age | Other directorships |
|---|---|---|---|---|
| Deputy Board Member | 2022 | — | — | |
| Chairman | 2021 | — | — | |
| Deputy Board Member | 2021 | — | — |
No shareholder data available.
Beneficial ownership (UBO) data access is restricted in Denmark as of September 2025 per the EU 6th AML Directive. Learn more.
No registered parent or subsidiaries
Board members of Ridahpharma AB also hold positions in 0 other companies.
| Person | Role here | Other companies |
|---|---|---|
| Adam Mohammed Ridahsson | Chief Executive Officer | 0 companies |
| Lars Michael Magnusson | Chief Auditor | 0 companies |
| Ghassan Imad Suleiman | Audit | 0 companies |
| Sara Nora Erbelli | Deputy Board Member | 0 companies |
| Dalia Ridahsson | Chairman | 0 companies |
| Sermed Sate Al Abbasi | Deputy Board Member | 0 companies |